Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi D - Benzinga

Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi D  Benzinga